WaveMan
WaveMan · Company
AZTR · Azitra, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AZTR Azitra (AZTR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001701478
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed

What the filings say about AZTR

Activist stakes (13D), 180 days
1 filing
Largest: 10.0% of the class

Azitra insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Azitra, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Staskey Norm
Chief Financial Officer
BUY
2024-04-01 SECtraded 2024-03-29
47,600
$10.0K
-96.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 13, 2024.
  • The trade is 93.2% of the 51,100 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Staskey Norm bought about $10.0K of AZTR on Mar 29, 2024; 13 funds added in the latest 13F quarter.
Whitfill Travis
Chief Operating Officer
BUY
2024-02-15 SECtraded 2024-02-13
15,000
$4.5K
-97.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 4.5% of the 334,500 shares held after it.
  • 2 other insiders bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Whitfill Travis bought about $4.5K of AZTR on Feb 13, 2024; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.
Staskey Norm
Chief Financial Officer
BUY
2024-02-15 SECtraded 2024-02-13
3,300
$990
-97.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 94.3% of the 3,500 shares held after it.
  • 2 other insiders bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Staskey Norm bought about $990 of AZTR on Feb 13, 2024; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.
Salva Francisco D.
President and CEO
BUY
2024-02-15 SECtraded 2024-02-13
333,300
$100.0K
-97.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 98.5% of the 338,300 shares held after it.
  • 2 other insiders bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Salva Francisco D. bought about $100.0K of AZTR on Feb 13, 2024; 2 other insiders bought within 30 days and 13 funds added in the latest 13F quarter.
Cavu Advisors, LLC
SELL
2023-06-23 SECtraded 2023-06-21
77,953
-
-99.8%
22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 17 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 81% of Pharma & Biotech
The situation: each line is one rule over one dataset
Salva Francisco D. disclosed a 5%+ stake (9.99%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AZTR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+186.5%12M
-87%+15%+116%+217%2025-102025-122026-022026-042026-062026-082026-10 2026-06-24 · Salva Francisco D. filed a 5%+ stake (9.99%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AZTR: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
87,083,029 sh
$8.9M
Dauntless Investment Group, LLC
11,292,186 sh
$1.9M
Nantahala Capital Management, LLC
4,427,226 sh
$742.9K
JANE STREET GROUP, LLC
248,433 sh
$41.7K
GEODE CAPITAL MANAGEMENT, LLC
95,409 sh
$16.0K

Congress trades in AZTR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Salva Francisco D.
Activist 13D · 2026-06-24
9.99%

AZTR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

AZTR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$82.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Multi-phase
1 active
What changed recently
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
2026-10-14 · Completion moved 2027-01-15 → 2027-07-15
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AZTR financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$11.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-256.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-190.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-249.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-12.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$7.5K$686.0K$284.0K
Operating income-$11.0M-$11.0M-$7.5M-$9.5M
Net income-$11.0M-$9.0M-$11.3M-$10.7M
EPS (diluted)-2.25-15.70-54.98-12.74
Operating cash flow-$11.2M-$10.2M-$7.4M-$8.3M
Cash$2.1M$4.6M$1.8M$3.5M
SEC XBRL, fiscal years, as known on 2026-10-27

AZTR Stock Sonar score 4/7 axes

Find similar shapesCompare

AZTR ranks highest on risk and compliance (70th percentile) and institutional and government (23rd), and lowest on growth (1st), among Pharma & Biotech peers.

Profitability
11
Inputs
  • Return on equity-256.7% · 13 pct, sector of 545
  • Return on assets-190.7% · 11 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-249.7% · 7 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
  • Short interest, % of float+4.7% · 60 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.6% · 80 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AZTR filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies